Published in Am J Gastroenterol on January 26, 2010
Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review. Hepat Mon (2013) 0.92
A longitudinal study evaluating the effects of interferon-alpha therapy on cognitive and psychiatric function in adults with chronic hepatitis C. J Psychosom Res (2014) 0.90
No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord (2011) 0.78
Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin. J Neurovirol (2016) 0.75
Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials (2014) 0.75
Reliability and validity studies of the WHO--Composite International Diagnostic Interview (CIDI): a critical review. J Psychiatr Res (1994) 11.08
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol (2004) 4.90
Reliability of alcohol use indices. The Lifetime Drinking History and the MAST. J Stud Alcohol (1982) 4.36
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc (2003) 2.83
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology (2002) 2.26
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol (2002) 2.05
Practice effects and the use of alternate forms in serial neuropsychological testing. Arch Clin Neuropsychol (2005) 1.91
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol (2004) 1.76
Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci (2003) 1.72
Mental status impairment in patients with West Haven grade zero hepatic encephalopathy: the role of HCV infection. J Gastroenterol (2007) 1.56
Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology (2005) 1.49
Characteristics of minimal hepatic encephalopathy. Metab Brain Dis (2004) 1.47
Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc (2003) 1.39
Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology (1999) 1.25
Testing cognitive function in elderly populations: the PROSPER study. PROspective Study of Pravastatin in the Elderly at Risk. J Neurol Neurosurg Psychiatry (2002) 1.16
Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci (2007) 1.10
Cerebral immune activation in chronic hepatitis C infection: a magnetic resonance spectroscopy study. J Hepatol (2008) 1.10
Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. J Neurovirol (2008) 1.08
Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS (2005) 1.08
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol (2005) 0.98
Monitoring cognitive changes: psychometric properties of six cognitive tests. Br J Clin Psychol (2004) 0.97
Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc (2005) 0.97
Minimal hepatic encephalopathy. Nat Clin Pract Gastroenterol Hepatol (2007) 0.94
Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C. Hepatology (2007) 0.89
Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C. Am J Gastroenterol (2008) 0.88
Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin Pharmacol Ther (2005) 0.88
Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis. J Clin Exp Neuropsychol (2006) 0.88
Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. J Affect Disord (2005) 0.87
Interferons and cognition. J Neurol Sci (2006) 0.80
Test-retest stability of the Continuous Visual Memory Test in elderly persons. Arch Clin Neuropsychol (1998) 0.76
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Retropubic versus transobturator midurethral slings for stress incontinence. N Engl J Med (2010) 7.95
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med (2012) 4.59
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med (2006) 4.09
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol (2003) 2.60
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Urodynamic measures do not predict stress continence outcomes after surgery for stress urinary incontinence in selected women. J Urol (2008) 2.43
Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A (2004) 2.30
Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology (2003) 2.14
A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology (2011) 2.08
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02
Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology (2011) 1.98
Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men. J Clin Endocrinol Metab (2007) 1.96
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology (2005) 1.93
Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology (2009) 1.80
Beyond the lower urinary tract: the association of urologic and sexual symptoms with common illnesses. Eur Urol (2007) 1.79
Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology (2006) 1.76
Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73
DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol (2007) 1.71
The effect of urodynamic testing on clinical diagnosis, treatment plan and outcomes in women undergoing stress urinary incontinence surgery. J Urol (2012) 1.64
The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol (2007) 1.58
Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol (2002) 1.57
Mayo's Older Americans Normative Studies: Age- and IQ-Adjusted Norms for the Trail-Making Test, the Stroop Test, and MAE Controlled Oral Word Association Test. Clin Neuropsychol (2005) 1.54
Baseline urodynamic predictors of treatment failure 1 year after mid urethral sling surgery. J Urol (2011) 1.53
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52
Contemporary review 2009: cognitive aging. J Geriatr Psychiatry Neurol (2010) 1.49
Design of the Value of Urodynamic Evaluation (ValUE) trial: A non-inferiority randomized trial of preoperative urodynamic investigations. Contemp Clin Trials (2009) 1.44
Preoperative voiding detrusor pressures do not predict stress incontinence surgery outcomes. Int Urogynecol J (2010) 1.39
Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol (2006) 1.38
Demographic and clinical predictors of treatment failure one year after midurethral sling surgery. Obstet Gynecol (2011) 1.35
Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology (2009) 1.35
A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology (2011) 1.33
Mayo's Older Americans Normative Studies: Age- and IQ-Adjusted Norms for the Auditory Verbal Learning Test and the Visual Spatial Learning Test. Clin Neuropsychol (2005) 1.22
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Face emotion perception and executive functioning deficits in depression. J Clin Exp Neuropsychol (2005) 1.19
Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology (2009) 1.18
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology (2006) 1.13
Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2010) 1.12
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology (2012) 1.12
Patient satisfaction with stress incontinence surgery. Neurourol Urodyn (2010) 1.09
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology (2009) 1.08
Urodynamic changes associated with successful stress urinary incontinence surgery: is a little tension a good thing? Urology (2011) 1.08
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology (2011) 1.07
Statistical methods to study timing of vulnerability with sparsely sampled data on environmental toxicants. Environ Health Perspect (2011) 1.06
Apathy and executive function in Alzheimer's disease. J Int Neuropsychol Soc (2002) 1.05
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther (2010) 1.04
Mayo's Older Americans Normative Studies: Age- and IQ-Adjusted Norms for the Wechsler Memory Scale--Revised. Clin Neuropsychol (2005) 1.04
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One (2011) 1.04
Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03
More advanced hepatic fibrosis in hispanics with chronic hepatitis C infection: role of patient demographics, hepatic necroinflammation, and steatosis. Am J Gastroenterol (2006) 1.03
Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology (2011) 1.02
Treatment success of retropubic and transobturator mid urethral slings at 24 months. J Urol (2012) 1.00
The sensitivity and psychometric properties of a brief computer-based cognitive screening battery in a depression clinic. Psychiatry Res (2007) 1.00
Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol (2005) 0.98
The effect of mode of delivery, parity, and birth weight on risk of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct (2007) 0.98
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology (2011) 0.98
Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology (2011) 0.95
The effects of severity of urine leakage on quality of life in Hispanic, white, and black men and women: the Boston community health survey. Urology (2009) 0.93
Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol (2006) 0.93
Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One (2012) 0.93
Mayo's Older Americans Normative Studies: Age- and IQ-Adjusted Norms for the Boston Naming Test, the MAE Token Test, and the Judgment of Line Orientation Test. Clin Neuropsychol (2005) 0.92
Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial. Aliment Pharmacol Ther (2008) 0.91
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. Hepatology (2008) 0.91